HIT Consultant November 7, 2025
What You Should Know:
– Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics announced the publication of foundational preclinical data in the peer-reviewed journal Cell Reports Medicine, the close of a $25M Series A1 financing round.
– In addition, the company appointed Dr. Thomas A. Buchholz as a clinical advisor. The funding brings the total raised in Series A financing to $40M.
Foundational Preclinical Data Validates Cancer-Selective Mechanism
The published study provides the most comprehensive validation to date of the ELANE pathway as a cancer-selective, immune-activating mechanism. Onchilles’ lead drug candidate, N17350, is a tumor-directed biologic that leverages this pathway to selectively kill cancer cells while sparing healthy tissue and activating a systemic immune response.
- Broad...
Today's Sponsors
Today's Sponsor